ESTRO 2022 - Abstract Book

S975

Abstract book

ESTRO 2022

ATAXIA

26 (22.6%) 26 (22.6%)

MOTOR DEFICIT

KPS ≥ 70 ≤ 60

93(80.8%) 22(19.1%)

LEPTOMENGEAL SPREAD YES

15 (13.04%) 100 (86.95%)

NO

HISTOPATHOLOGY CLASSIC

68 (59.1%) 31 (26.9%) 16 (13.9%)

DESMOPLASTIC

ANAPLASTIC

TABLE 2

VARIABLE

N

%

SURGERY

115

100

GTE

92

80%

NTE

14

12.2%

STE

7

6.1%

BIOPSY

2

1.7%

CSI (Median duration 48 days) -3DCRT

102

88.69%

LOW DOSE CSI

38

33.04%

STANDARD DOSE CSI

64

62.74%

CONCURRENT CHEMOTHERAPY

38

33.04%

ADJUVANT CHEMOTHERAPY

91

79.1%

Conclusion Ongoing studies are risk stratifying the patients and tailoring the treatment based on the molecular subgroups. Till the results of these studies are available, maximum safe resection followed by CSI and chemotherapy constitutes the standard of care in all medulloblastoma patients.

PO-1150 Cost-effectiveness of treatment strategies for spinal metastases

R. Kowalchuk 1 , T. Mullikin 2 , D. Kim 3 , J. Morris 3 , D. Ebner 1 , W. Harmsen 4 , K. Merrell 1 , S. Beriwal 5 , M. Waddle 1 , H. Kim 6

1 Mayo Clinic, Radiation Oncology, Rochester, USA; 2 Duke University, Radiation Oncology, Durham, USA; 3 Mayo Clinic, Radiology, Rochester, USA; 4 Mayo Clinic, Statistics, Rochester, USA; 5 Allegheny Health Networks, Academic Chief, Pittsburgh, USA; 6 University of Pittsburgh Medical Center, Statistics, Pittsburgh, USA Purpose or Objective Patients with spinal metastases have a range of palliative treatment options, including radiotherapy and radiofrequency ablation (RFA). Recent data has shown higher complete pain response with SBRT in comparison to standard palliative RT. We seek to assess the cost-effectiveness of stereotactic body radiation therapy (SBRT, 24 Gy in 2 fractions), conventional palliative external beam radiation (EBRT, 8 Gy in 1 fraction) and RFA. Materials and Methods A Markov state transition model was constructed comparing the following three treatment strategies: single-fraction EBRT, two-fraction SBRT, and RFA for palliative treatment of painful spinal metastases. Model parameters were derived from prospective clinical trial data whenever possible (Table 1). Strategies were compared using the incremental cost- effectiveness ratio (ICER), with effectiveness in quality-adjusted life years (QALYs) and a willingness-to-pay (WTP) threshold